Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis

Inclusion Criteria: * IBM defined by the Benveniste \& Hilton-Jones ( Neuromuscul Disord. 2010;20: 414-21) or Llyod criteria (Neurology 2014; 83: 426-433) Exclusion Criteria: * Impossiblility to walk 10 meters * Hypersensitivity to rapamycin or one compound of the oral solution * Severe respiratory insufficiency (FVC \< 50% and/or FEV1 \< 50%) * Severe chronic kidney disease (Estimated Glomerular Filtration Rate \< 15 ml/min and/or proteinuria \> 0.3 g/24h) * Chronic liver disease (cirrhosis and/or ALT/AST \> 2.5 normal values) * Cancer non in remission (necessitating specific treatment) during the past 12 months * Connective Tissue Disease non in remission (necessitating specific treatment) during the past 12 months * Pregnancy * Seropositivity for HIV, HCV or HBV * Total cholesterolemia \> 8 mmol/l * Triglyceridemia \> 5 mmol/l * Hemoglobinemia \< 11 g/dL * Thrombopenia \< 100 000/mm3 * Neutropenia \< 1500/ mm3 * Lymphopenia \< 1000/ mm3